Triamcinolone
- PDF / 169,916 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 26 Downloads / 145 Views
1 S
Sterile endophthalmitis following off-label use of triamcinolone: 3 case reports In a study, three patients [two men and one woman] aged 18–42 years were described, who developed sterile endophthalmitis following intravitreal administration of triamcinolone for intermediate uveitis in the right eye. The intravitreal route of triamcinolone administration was considered as off-label. The patients, who had intermediate uveitis in the right eye, were taken to the operation theatre to receive a single intravitreal injection of triamcinolone [triamcinolone acetonide] in the affected right eye. After topical disinfection with povidone-iodine, the aseptic field and eyelid speculum were applied. Oxybuprocaine drops were instilled for local anaesthesia followed by unspecified local antibiotic drops. Thereafter, the patients received a single intravitreal injection of triamcinolone [triamcinolone acetonide] 4mg in the affected right eye through the inferotemporal pars plana, 4mm from the limbus. The intravitreal route of triamcinolone administration was considered as off-label. After 24h of injection, the patients showed a decreased visual acuity and vitreous inflammation in their right eye. After performing the ocular examinations, it was found that the all three patients had developed an acute sterile inflammatory reaction to triamcinolone in their right eye. Consequently, the patients received treatment with prednisolone acetate, topical antibiotics and cycloplegic eye drops [specific drug not stated]. The vitreous inflammation resolved within 3 weeks in one patient and within 4 weeks in the other two patients. Since the vitreous inflammation resolved without the use of intravitreal antibiotics, it was confirmed that the patients had sterile endophthalmitis instead of infectious endophthalmitis. Suta MC, et al. Triamcinolone acetonide induces sterile endophthalmitis in patients with intermediate uveitis: A case report series. Experimental and Therapeutic Medicine 20: 2524-2528, No. 3, Sep 2020. Available from: URL: http://doi.org/10.3892/etm.2020.8883 803501250
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
